GW Pharmaceuticals announces appointments to Board of Directors


GW Pharmaceuticals, a biopharmaceutical company focused on discovering, developing and commercialising novel therapeutics from its proprietary cannabinoid product platform, announced the appointment of three new independent members to its Board of Directors, bringing the GW Board to a total of eight members.

Joining the Board of Directors are Catherine Mackey, Alicia Secor and Lord William Waldegrave.

“We are very pleased to welcome these outstanding individuals to the GW Board. The support and guidance of these accomplished leaders will be valuable as GW embarks on the next stage of its journey as a commercial stage company,” said Dr Geoffrey Guy, GW’s Founder and Chairman of the Board of Directors.

“Their wealth of experience, talent and expertise offer additive value to our Board profile, as well as expanding the number of independent representatives.”

Dr Catherine Mackey

Dr Mackey is an experienced corporate executive, director and advisor with more than thirty years of accomplishment in the biotechnology, pharmaceutical and agricultural industries.

She is currently CEO of CYPrus Therapeutics and Chairman of the Board of Cour Pharmaceutical Development. In addition, she serves on the Board of Directors of Rady Children’s Hospital and as an advisor to several companies.

Dr Mackey previously served as Senior VP of Pfizer Worldwide R&D and Director, of Pfizer’s La Jolla Laboratories, where she built Pfizer La Jolla into one of Pfizer’s main pharmaceutical research and development sites with more than 1000 employees and a robust drug pipeline.

Prior to that role she served as head of Strategic Alliances and also Genomic and Proteomic Sciences for Pfizer. Dr Mackey spent the first part of her career in agricultural biotechnology, including being VP of DEKALB Genetics, Dr Mackey received her BS and PhD degrees in microbiology and genetics from Cornell University.

Alicia Secor

Alicia Secor is currently President and CEO of Juniper Pharmaceuticals. Secor brings more than 25 years of leadership experience as a life sciences executive, with a track record in leading businesses and advancing products from clinical development through regulatory approval, commercialisation and global expansion across several therapeutic areas.

Secor was previously CCO at Zafgen and Senior VP and COO at Synageva BioPharma Corp. Secor spent 15 years at Genzyme Corporation in diverse leadership roles, most recently as the Global General Manager for the Metabolic Disease Business.

During her tenure at Genzyme, Secor led fully integrated businesses, successfully launching products and achieving sustained revenue growth. Prior to Genzyme, Secor held positions at Alkermes, in business development and at Centocor, (a Johnson & Johnson Company) in clinical and commercial operations.

She began her career at Pfizer as a hospital-based sales representative. Secor received an MBA from Northeastern University and a BS in Healthcare Administration from the University of New Hampshire and serves as a member of the Board of Directors for the Foundation for Prader-Willi Research (FPWR).

William Waldegrave (Lord Waldegrave of North Hill)

Lord Waldegrave served as a Conservative Member of the British Parliament from 1979 to 1997 including sixteen years as a Government Minister, of which seven years were as a Cabinet Minister (Minister of Agriculture, Chief Secretary of the Treasury, Secretary of State for Health and Chancellor of the Duchy of Lancaster with responsibility for the Civil Service Reform and Science).

Educated at Oxford University and Harvard (a Kennedy Scholar), before entering Parliament he worked in the Cabinet Office in Whitehall; as Political Secretary to Prime Minister Edward Heath; and for GEC. Lord Waldegrave is currently Provost of Eton College, Chancellor of Reading University and a Distinguished Fellow of All Souls College, Oxford and an Honorary Fellow of Corpus Christi College, Oxford.

From 1998-2008 he worked at Deutsche Kleinwort Benson and UBS. From 1998–2015, he served as Chairman of Biotechnology Growth Trust. Lord Waldegrave was appointed Chairman of Coutts in January 2014 and is Chairman of the Royal Mint Advisory Committee, former Chairman of the Rhodes Trust, a Founder Trustee of the Mandela Rhodes Foundation (South Africa), and a former Chairman of the National Museum of Science and Industry.

Sign up for your free email newsletter